Search Results

You are looking at 71 - 80 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

CLO23-050: Total Neoadjuvant Chemotherapy Followed by HIPEC and Curative Surgery in Treatment of Locally Advanced Gastric Cancer

Veronika Patsko, Oleksii Dobrzhankiy, and Yurii Kondratsky

toxicity: leukopenia and neutropenia grade 3–4 in 5 patients (62.5%) and mucosal toxicity: diarrhea grade 2 in 4 (50%) patients, oral mucositis grade 1-2 in 3 (37.5%) and 2 (25%) patients respectively. Conversion rate to negative peritoneal cytology was 80

Full access

CLO20-049: Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol-Free Melphalan (Evomela®) and Generic Melphalan

Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung, and Taewoong Choi

-free melphalan and thirty-six received generic melphalan; both groups had similar demographics, performance status and ISS stage ( Table 1 ). There was no statistically significant difference in time to count recovery, toxicities (mucositis, febrile neutropenia

Full access

NCCN News

information, visit NCCN.org/orp . NCCN Releases New Patient Guidelines on Anemia and Neutropenia NCCN has published new NCCN Guidelines for Patients: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and

Full access

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

Gary H. Lyman

a prospective nationwide study of oncology practice . J Natl Compr Canc Netw 2008 ; 6 : 109 – 118 . 2 Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer

Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

years) had improved median PFS and RR but no improvement in median OS. 11 The most common grade 3 or higher AEs in the bevacizumab arm were neutropenia (26%), hypertension (7%), febrile neutropenia (5%), and bleeding events (4%). 9 Compared with

Full access

Identification of Risk Factors for Chemotherapy-Related 30-Day Readmissions

Jeremy Lund, Angela Pearson, and Georgia Keriazes

readmitting diagnosis or ICD-9 code. Criteria for CRR included diagnosis of febrile neutropenia, other known toxicity of administered chemotherapy agent, and documented diagnosis of CRR by the oncologist. A multidisciplinary panel (medical oncologist, oncology

Full access

A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States

Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna

neutropenia (neutrophil count <1,500/mcL) occurring during the first 4 weeks after initiation of treatment. To minimize immortal time bias, follow-up time in this analysis was defined as time in months starting 4 weeks after initiation of treatment. A final

Full access

Antimicrobial Stewardship in Cancer Patients: The Time is Now

Samuel L. Aitken, Jerod L. Nagel, Lilian Abbo, William Alegria, Jason N. Barreto, Sanjeet Dadwal, Alison G. Freifeld, Rupali Jain, Steven A. Pergam, Frank P. Tverdek, Susan K. Seo, and on behalf of the Antimicrobial Stewardship in Cancer Consortium ASCC

-specific, evidence-based guidelines and clinical pathways to standardize prescribing is not only feasible but necessary. Examples of highly used pathways in patients with cancer include the management of fever and neutropenia, antifungal prophylaxis and treatment

Full access

Diagnostic Strategies for Invasive Fungal Infections in Patients With Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients

Maxim Norkin and John R. Wingard

Because of prolonged neutropenia and severe immunosuppression, patients with hematologic malignancies (HMs) and hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive fungal infections (IFIs), which are associated with

Full access

The Role of Biosimilars

Andrew D. Zelenetz and Pamela S. Becker

indications as filgrastim: to treat patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia (FN); patients with acute myeloid leukemia receiving induction or